President Donald Trump unwrapped a massive drug pricing policy as CMS prepares for the next round of Medicare drug price negotiations; Vinay Prasad to take the helm at the FDA’s Center for Biologics ...

GSK plans to purchase an experimental drug for the liver disease MASH from Boston Pharmaceuticals for $1.2 billion upfront.

Hospitals pay provider taxes, helping states spend more on Medicaid and increase the amounts paid by the federal government.

The drive revolves around a "10-for-one" policy laid out in a Trump executive order at the end of January, which demanded ...

Japanese drugmaker Takeda has suffered a blow to its late-stage pipeline, after the FDA rejected its marketing application for TAK-721, a drug candidate that is trying to be the first approved ...

In the space of four days, the number of FDA-approved therapies for ultra-rare genetic disorder Niemann-Pick disease has gone from zero to two, transforming the prospects for patients. IntraBio's ...

Novo Nordisk applied to the FDA for approval of semaglutide in obesity in December, using an acquired priority voucher to speed up the review time. Looming on the horizon is Lilly's tirzepatide ...

People with a form of severe epilepsy will now be able to get NHS access to a new drug from UCB, Fintepla, that could significantly reduce their seizures. The NHS will fund Fintepla (fenfluramine ...

Novartis' soon-to-be-divested Sandoz unit has positive clinical trial data in hand for a biosimilar of Amgen's blockbuster osteoporosis therapy Prolia (denosumab), clearing the way for regulatory ...